False
August 10, 2026
Johnson & Johnson partners with Sail Biomedicines, an FDA advisory committee votes against deramiocel for Duchenne cardiomyopathy, and researchers uncover factors influencing CAR T and CAR NK outcomes
3 min read
August 3, 2026
A previously undisclosed death in China raises questions about gene-editing oversight, deramiocel meets its Phase 3 Duchenne endpoint, and researchers identify a source of CAR NK dysfunction
4 min read
July 27, 2026
Allogeneic CAR T produces durable responses in advanced kidney cancer, the FDA clears a CD22-directed in vivo therapy, and Repligen agrees to acquire BioLife Solutions for $1.5 billion
4 min read
July 20, 2026
First-in-human diabetes cell replacement, early iPSC-derived CAR T data in systemic sclerosis, AAV gene therapy for fragile X syndrome, and fresh funding for off-the-shelf CAR T
4 min read
July 14, 2026
Researchers retrofit a lab-scale monoclonal antibody purification platform with automation, OPC-UA connectivity, and model-based flow control
3 min read
July 13, 2026
A targeted radiopharmaceutical improves CAR T activity in neuroblastoma models, engineered Tregs suppress allergic asthma, and new gene therapy platforms target MMA and the brain
4 min read
July 7, 2026
First Treg-based cell therapy approved, FDA advanced therapy office faces fresh turnover, and preclinical CAR T studies target rare blood cancers and glioblastoma
5 min read
July 6, 2026
A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models
2 min read
June 30, 2026
A single infusion of engineered T cells degraded soluble TNF and produced durable disease control in mice
2 min read
False